Dr. Bradley on Adverse Events Associated With Enzalutamide and Apalutamide in Prostate Cancer
July 26th 2019Deborah A. Bradley, MD, medical oncologist, Levine Cancer Institute, Atrium Health, discusses the adverse events (AEs) that are associated with enzalutamide (Xtandi) and apalutamide (Erleada) in prostate cancer.
Read More